TrialPath
Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT07332481 · EMD Serono
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-1)
About this study
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.
Eligibility criteria
Inclusion Criteria * Vaccinations are up to date according to local guidelines/recommendations. Recombinant zoster vaccination is encouraged but not mandatory. * Participants with diagnosis of Discoid Lupus Erythematosus (DLE) and/or Subacute Cutaneous Lupus Erythematosus (SCLE) documented in medical history, with or without Systemic Lupus Erythematosus (SLE). * Participants with active Acute Cutaneous Lupus Erythematosus (ACLE) as sole cutaneous manifestations is allowed in the presence of SLE and should be present for at least 6 weeks prior to the Screening visit. * Participants with diagnosis of SLE fulfilling the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria, must have active DLE and/or SCLE and/or ACLE. For participants with SLE: * Participants with diagnosis of SLE and fulfill EULAR/ACR 2019 classification criteria. * Participants with disease duration (cutaneous disease and, where applicable, SLE) of \>= 6 months from time of diagnosis to Screening. * Participants with CLASI-A score \>= 8 at Screening and Day 1 visits. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria * Participants with primary diagnosis of autoimmune rheumatic disease (e.g., systemic sclerosis, rheumatoid arthritis) other than Cutaneous Lupus Erythematosus (CLE) and SLE. * Participants with any condition including dermatological diseases other than cutaneous manifestations of lupus (e.g. psoriasis), any uncontrolled disease (e.g. asthma, chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasis, pulmonary arterial hypertension), or life-threatening manifestations of lupus (e.g. active systemic vasculitis) that in Investigator's or Sponsor/designee's opinion constitutes inappropriate risk or contraindication for participation. * Participants with drug-induced lupus (SLE or CLE). * Participants with active lupus nephritis on induction therapy, or induction therapy completed within 3 months of the Screening visit (stable maintenance therapy with either mycophenolate azathioprine or an oral calcineurin inhibitor is allowed). * Participants with Urine Protein-to-Creatinine Ratio (UPCR) greater than (\>) 339 milligrams per millimole (mg/mmol), and/or estimated Glomerular Filtration Rate (eGFR) less than 40 milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m\^2), as calculated by the Modification of Diet in Renal Disease (MDRD) equation. * Participants with any active signs, symptoms, or diagnoses considered related to Central Nervous System (CNS) lupus within the past 3 months, or any history of uncontrolled seizures. * Other protocol-defined exclusion criteria may apply.
Study design
Enrollment target: 202 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2026-03-10
Estimated completion: 2029-05-24
Last updated: 2026-11-04
Interventions
Drug: EnpatoranDrug: PlaceboDrug: Standard of care (SoC)
Primary outcomes
  • • Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 70 Response, Defined as >= 70 Percent (%) Decrease in CLASI-A Score From Baseline (At Week 24)
Sponsor
EMD Serono Research & Development Institute, Inc. · industry
With: Merck KGaA, Darmstadt, Germany
Contacts & investigators
ContactCommunication Center · contact · service@emdgroup.com · +49 6151 72 5200
InvestigatorMedical Responsible · study_director, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
All locations (74)
Dermatology Research Associates - 300204025Recruiting
Los Angeles, California, United States
Cohen Medical CentersRecruiting
Thousand Oaks, California, United States
GNP Research at Mark Jaffe, MDRecruiting
Cooper City, Florida, United States
Advance Medical Research CenterRecruiting
Miami, Florida, United States
Diverse Clinical Research LLCRecruiting
Miami, Florida, United States
D&H National Research Centers, Inc.Recruiting
Tamarac, Florida, United States
Clinical Research of West Florida, Inc.Recruiting
Tampa, Florida, United States
Emory University School of MedicineRecruiting
Atlanta, Georgia, United States
Revival Research Institute, LLCRecruiting
Troy, Michigan, United States
Allen ArthritisRecruiting
Allen, Texas, United States
Arthritis and Rheumatology Research Institute PLLCRecruiting
Allen, Texas, United States
Arthritis Care of TexasRecruiting
Corpus Christi, Texas, United States
John Hunter Hospital - PARENTRecruiting
New Lambton Heights, New South Wales, Australia
Rheumatology Research Unit Sunshine CoastRecruiting
Maroochydore, Queensland, Australia
The Alfred Hospital - PARENTRecruiting
Melbourne, Victoria, Australia
UZ Leuven - Internal MedicineRecruiting
Leuven, Belgium
HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do CearáRecruiting
Fortaleza, Ceará, Brazil
Clínica SER da BahiaRecruiting
Salvador, Estado de Bahia, Brazil
IPC MT Instituto de Pesquisas Clinicas do Mato GrossoRecruiting
Cuiabá, Mato Grosso, Brazil
Freire Pesquisa ClinicaRecruiting
Belo Horizonte, Minas Gerais, Brazil
Hospital de Câncer de Barretos - Fundação Pio XII - Hospital de Amor de BarretosRecruiting
Barretos, São Paulo, Brazil
DCC V Plovdiv Sv. Archbishop Luka EOODRecruiting
Plovdiv, Bulgaria
Ambulatory for Specialized Medical Help - skin and venereal diseasesRecruiting
Sofia, Bulgaria
Guangdong Provincial People's HospitalRecruiting
Guangzhou, Guangdong, China
Ganzhou People's Hospital - 300165192Recruiting
Ganzhou, Jiangxi, China
CHU Saint Etienne - Hôpital Nord - service de medecine interneRecruiting
Saint-Étienne-de-Montluc, Pays de la Loire Region, France
Hopital Tenon - service dermatologie et centre d'allergieRecruiting
Paris, France
Elbekliniken Buxtehude GmbH - DermatologieRecruiting
Buxtehude, Lower Saxony, Germany
Charité - Campus Charité Mitte - Klinik fuer Dermatol., Venerol., AllergologieRecruiting
Berlin, Germany
Universitaetsklinikum Carl Gustav Carus TU DresdenRecruiting
Dresden, Germany
Chaim Sheba Medical Center - ptRecruiting
Ramat Gan, Israel
Azienda USL Toscana Centro - Ospedale Piero PalagiRecruiting
Florence, Firenze, Italy
Università Campus Bio-Medico di Roma - UOC ReumatologiaRecruiting
Roma, Italy
JCHO Chukyo Hospital - Dept of DermatologyRecruiting
Nagoya, Aichi-ken, Japan
NHO Chibahigashi National Hospital - Dept of Allergy/RheumatologyRecruiting
Chiba, Chiba, Japan
Hospital of the University of Occupational and Environmental Health - Dept of DermatologyRecruiting
Kitakyushu-shi, Fukuoka, Japan
Fukushima Medical University Hospital - Dept of Rheumatology/ImmunologyRecruiting
Fukushima, Fukushima, Japan
NHO Asahikawa Medical Center - Dept of GastroenterologyRecruiting
Asahikawa-shi, Hokkaido, Japan
Sapporo City General Hospital - Dept of Rheumatology/ImmunologyRecruiting
Sapporo, Hokkaido, Japan
Kobe University Hospital - Dept of Immunology/RheumatologyRecruiting
Kobe, Hyōgo, Japan
Kanazawa University Hospital - Dept of Rheumatology/ImmunologyRecruiting
Kanazawa, Ishikawa-ken, Japan
Yokohama City University Hospital - Dept of DermatologyRecruiting
Yokohama, Kanagawa, Japan
Tohoku Medical and Pharmaceutical University Hospital - Dept of Hematology/RheumatologyRecruiting
Sendai, Miyagi, Japan
Okayama University Hospital - Dept of Rheumatology/ImmunologyRecruiting
Okayama, Okayama-ken, Japan
The University of Osaka Hospital - Dept of DermatologyRecruiting
Suita-shi, Osaka, Japan
Institute of Science Tokyo Hospital - Dept of DermatologyRecruiting
Bunkyo-ku, Tokyo, Japan
Nihon University Itabashi Hospital - Dept of Hematology/ImmunologyRecruiting
tabashi City, Tokyo, Japan
St. Luke's International Hospital - Dept of Immunology/AllergyRecruiting
Chūōku, Tokyo-To, Japan
University of Yamanashi Hospital - Dept of Rheumatology/ImmunologyRecruiting
Chūō, Yamanashi, Japan
Centrum Badan Klinicznych JCIRecruiting
Krakow, Poland
ETG Lublin - ETG NETWORK Sp. z o.o.Recruiting
Lublin, Poland
Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp. z o.o.Recruiting
Malbork, Poland
Uniwersytecki Szpital Kliniczny im Fryderyka Chopina w Rzeszowie - Klinika Dermatologii i Dermatologii OnkologicznejRecruiting
Rzeszów, Poland
SOMED CRRecruiting
Rzeszów, Poland
REUMA CENTRUM Specjalistyczna Praktyka Lekarska Dr n. med. Jakub TreflerRecruiting
Warsaw, Poland
Velocity ZamoscRecruiting
Zamość, Poland
Futuremeds S R L.Recruiting
Brasov, Romania
Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto - Dermatovenerologicka klinikaRecruiting
Bratislava, Slovakia
Artromac n.o. - Reumatologicka ambulanciaRecruiting
Košice, Slovakia
Korea University Ansan Hospital - 300133335Recruiting
Ansan-si, Gyeonggi-do, South Korea
Seoul National University Bundang HospitalRecruiting
Seongnam-si, Gyeonggi-do, South Korea
Gachon University Gil Medical CenterRecruiting
Incheon, South Korea
Hanyang University Seoul Hospital - 300186741Recruiting
Seoul, South Korea
Complejo Hospitalario Universitario de Santiago - Dermatology UnitRecruiting
Santiago de Compostela, La Coruña, Spain
Complejo Hospitalario de Navarra - NefrologiaRecruiting
Pamplona, Navarre, Spain
Hospital General Universitario de Valencia - RheumatologyRecruiting
Valencia, Spain
Universitaetsspital Basel - Klinik fuer DermatologieRecruiting
Basel, Switzerland
Kantonsspital St. Gallen - Klinik f. Dermatologie, Venerologie u AllergologieRecruiting
Sankt Gallen, Switzerland
China Medical University HospitalRecruiting
Taichung, Taiwan
Chi Mei Medical Center - 300192662Recruiting
Tainan, Taiwan
Thammasat University HospitalRecruiting
Amphur Klongluang, Changwat Pathum Thani, Thailand
Ramathibodi Hospital - 300195177Recruiting
Bangkok, Thailand
Whipps Cross University Hospital - Dept of RheumatologyRecruiting
London, Greater London, United Kingdom
Freeman Hospital - Dept of RheumatologyRecruiting
Newcastle upon Tyne, Tyne & Wear, United Kingdom
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease · TrialPath